During the annual meeting of the American Society of Clinical Oncology, a cell therapy posted clinical data that could broaden its use in multiple myeloma. In other developments, the class of drugs called ADCs continue to make progress and a novel brain cancer drug has Phase 3 data that support its use as a new treatment option.
The HER2 protein targeted by the approved cancer drug Enhertu is found on a wide range of tumors. Interim Phase 2 data reported at the annual meeting of the American Society of Clinical Oncology suggest the AstraZeneca and Daiichi Sankyo drug has potential to treat many of these cancers.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In a confirmatory Phase 3 test of ImmunoGen’s Elahere, the ovarian cancer drug handily beat chemotherapy with results that clinicians say could make the treatment the new standard of care for certain patients. The data were presented during the annual meeting of the American Society of Clinical Oncology.
A Servier drug candidate acquired as part of a $1.8 billion deal kept a particular type of brain cancer from progressing in a Phase 3 clinical trial. The study results were presented during the 2023 annual meeting of the American Society of Clinical Oncology.
A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six months—there were no detectable signs of the cancer. These early data presented at ASCO suggest that rectal cancer with a particular genetic signature might be treatable with this immunotherapy in lieu of the standard regimen of chemotherapy, radiation, and surgery.
Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some of the news highlights from the biggest cancer conference of the year.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
PMV Pharmaceuticals has its first clinical data showing that its lead therapeutic candidate can hit p53, a tumor-suppressing protein long thought to be undruggable. After reporting the preliminary data during ASCO, PMV said it plans to continue the Phase 1 study with the goal of advancing to Phase 2 early next year.
During the annual meeting of the American Society of Clinical Oncology, AstraZeneca and Daiichi Sankyo reported pivotal clinical trial data showing that their partnered cancer drug Enhertu can treat a group of patients previously thought to be out of reach for a targeted therapy. The results suggest use of this FDA-approved drug could significantly expand to more breast cancer patients.
The American Society of Clinical Oncology’s annual meeting begins this week, including the presentation of more than 2,800 abstracts. Amgen, Roche, and Sierra Oncology are among the companies with key presentations at this year’s gathering.
The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Cancer drug developer Merus has encouraging early results indicating its drug can address several different types of tumors characterized by NRG1, a rare gene fusion. The company believes the data could support a regulatory filing for the bispecific antibody drug.
Bristol Myers Squibb reported Phase 3 data that show its experimental cancer immunotherapy relatlimab, combined with the company's blockbuster drug Opdivo, was better at stopping melanoma from progressing. BMS will present the data at the upcoming annual meeting of the American Society of Clinical Oncology.
In data at the ASCO meeting last week, Grail showed a 1 percent false-positive rate. While that number seems likely to go down, even such a low rate can make a significant difference for patients.
While isatuximab with Celgene's Pomalyst beat Pomalyst with steroid alone, the bigger question is how it will fare on the market versus J&J's Darzalex, which will likely soon be available as an easier-to-use subcutaneous injection.
It remains unclear how many patients will relapse without the BCMA antigen, which would complicate their ability to use many CAR-T cell therapies later on. However, an expert said the drug's safety could be a challenge.